Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MGNX | PRESS-RELEASE | mixed | 6/10 | MacroGenics is selling its GMP drug substance manufacturing operations to Bora Pharmaceuticals for a $122.5 million upfr | May 11, 2026 |
| BCDA | PRESS-RELEASE | neutral | 1/10 | BioCardia, Inc. announced it will host a conference call on May 15, 2026 to discuss its Q1 2026 results. | May 11, 2026 |
| TNXP | 8-K | bearish | 6/10 | Tonix Pharmaceuticals reported Q1 2026 revenue of $6.9M, up 183% YoY from $2.4M, driven by the TONMYA launch ($3.7M in i | May 11, 2026 |
| BHST | 6-K | neutral | 2/10 | BioHarvest Sciences announced a strategic leadership transition: Co-Founder and Executive Chairman Zaki Rakib succeeds I | May 11, 2026 |
| WST | 8-K | bearish | 7/10 | West Pharmaceutical (WST) disclosed a material cybersecurity attack on May 7, 2026, with data exfiltration and system en | May 11, 2026 |
| BMEA | 8-K | neutral | 4/10 | Biomea Fusion reported Q1 2026 net loss of $12.4M ($0.17/share), narrower than the $29.3M loss ($0.80/share) in Q1 2025, | May 11, 2026 |
| BMEA | PRESS-RELEASE | neutral | 5/10 | Biomea Fusion reported Q1 2026 net loss of $12.4M ($0.17/share), significantly narrower than the $29.3M loss in Q1 2025, | May 11, 2026 |
| LONA | DEFA14A | neutral | 2/10 | LeonaBio, Inc. filed a DEFA14A (additional definitive proxy soliciting materials) providing notice of its 2026 Annual Me | May 11, 2026 |
| ARQT | 144 | neutral | 1/10 | Director Patrick Burnett filed a Form 144 notice of intent to sell 222 shares of Arcutis Biotherapeutics (ARQT) worth ap | May 11, 2026 |
| PHVS | 6-K | neutral | 4/10 | Pharvaris closed an underwritten public offering of 4,455,863 ordinary shares at $29.68 per share, raising approximately | May 11, 2026 |
| AVBP | 424B5 | bearish | 6/10 | ArriVent BioPharma filed a 424B5 prospectus supplement for an at-the-market (ATM) offering of up to $250 million in comm | May 11, 2026 |
| KYMR | 144 | neutral | 2/10 | Director Elena Ridloff filed a Form 144 to sell 3,000 shares of Kymera Therapeutics common stock, with an estimated mark | May 11, 2026 |
| HOWL | 144 | bearish | 6/10 | Two affiliated MPM entities (MPM Asset Management LLC and MPM Oncology Innovations Fund LP) filed Form 144 notices on Ma | May 11, 2026 |
| SCYX | PRESS-RELEASE | bearish | 7/10 | SCYNEXIS reported Q1 2026 results with a GAAP net loss of $0.42 per share, significantly wider than the consensus estima | May 11, 2026 |
| MLYS | 144 | neutral | 2/10 | Officer David Rodman filed a Form 144 notice of intent to sell 2,171 shares of Mineralys Therapeutics common stock, valu | May 11, 2026 |
| RAPP | 144 | bearish | 5/10 | Third Rock Ventures V, L.P., a 10% stockholder, filed a Form 144 to sell 133,618 shares of Rapport Therapeutics common s | May 11, 2026 |
| CPRX | PRESS-RELEASE | bearish | 8/10 | Catalyst Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.50 on total revenue of $149.4M, missing the consensus e | May 11, 2026 |
| FF | 8-K | mixed | 6/10 | FutureFuel reported Q1 2026 revenue of $32.0M (+82.2% YoY) but a net loss of ($20.6)M, wider than the ($18.1)M loss a ye | May 11, 2026 |
| ABCL | 8-K | bullish | 7/10 | AbCellera reported Q1 2026 revenue of $8.3M (up 96% YoY from $4.2M) and a net loss of $43.2M ($-0.14/share), narrower th | May 11, 2026 |
| CATX | 8-K | neutral | 4/10 | Perspective Therapeutics reported Q1 2026 results with a net loss of $26.2M ($0.25/share), widening from $18.2M loss in | May 11, 2026 |
| HROW | 8-K | mixed | 6/10 | Harrow reported Q1 2026 revenue of $44.2M (-8% YoY), missing consensus of $52.5M, and a GAAP net loss of $27.6M (-$0.74/ | May 11, 2026 |
| TTRX | 8-K | neutral | 4/10 | Turn Therapeutics reported Q1 2026 results: net loss of $0.97M ($0.03/share) vs $0.33M ($0.01/share) a year ago, with no | May 11, 2026 |
| PHVS | PRESS-RELEASE | neutral | 5/10 | Pharvaris closed a $132.3M underwritten offering of 4.46M ordinary shares, including full exercise of the underwriters' | May 11, 2026 |
| MGX | 8-K | neutral | 4/10 | Metagenomi Therapeutics reported Q1 2026 financial results, with collaboration revenue of $1.2M (down 70% YoY from $4.1M | May 11, 2026 |
| OCS | PRESS-RELEASE | neutral | 5/10 | Oculis reported Q1 2026 EPS of CHF -0.49 (vs consensus $-0.41), a miss of ~2.7% on a USD-converted basis. The company hi | May 11, 2026 |
| SANA | PRESS-RELEASE | bearish | 6/10 | Sana Biotechnology reported Q1 2026 GAAP net loss of $0.17 per share, slightly better than the $0.21 loss in Q1 2025 but | May 11, 2026 |
| HROW | PRESS-RELEASE | mixed | 6/10 | Harrow reported Q1 2026 revenue of $44.2M, down 7.6% YoY from $47.8M, and a GAAP net loss per share of -$0.74, significa | May 11, 2026 |
| ELTX | 8-K | neutral | 4/10 | Elicio Therapeutics reported Q1 2026 results with a net loss of $11.8M ($0.65 per share), wider than the $11.2M loss in | May 11, 2026 |
| MGX | PRESS-RELEASE | bearish | 6/10 | Metagenomi reported Q1 2026 EPS of -$0.61, missing consensus of -$0.55 by 10.9%, and collaboration revenue of $1.25M, we | May 11, 2026 |
| KYNB | PRESS-RELEASE | mixed | 5/10 | Kyntra Bio reported Q1 2026 revenue of $3.7M (above $1.6M consensus) but EPS of -$3.74 missed the -$3.35 consensus by 11 | May 11, 2026 |